menu
    • menu
    [{"orgOrder":0,"company":"Beximco Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BANGLADESH","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Beximco Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Beximco Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Beximco Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"PhysIQ","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InCarda Therapeutics \/ PhysIQ","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Therapeutics \/ PhysIQ"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InCarda Therapeutics \/ Deerfield Management","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Therapeutics \/ Deerfield Management"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InCarda Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InCarda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InCarda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Flecainide Acetate

    Menu

    Flecainide Acetate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    InCarda Therapeutics

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    InCarda Therapeutics

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Flecainide

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    InCarda Announces RESTORE-1 Phase 3 Trial Results and Continued Development Plans

    Details : FlecIH-103 is a novel inhaled drug designed to rapidly deliver flecainide acetate, to the heart via the lungs to restore normal sinus rhythm in patient’s symptoms recurrent PAF.

    Product Name : InRhythm

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    September 30, 2024

    Lead Product(s) : Flecainide

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    InCarda Therapeutics

    U.S.A arrow
    Plastics Recycling EU
    Not Confirmed

    InCarda Therapeutics

    U.S.A arrow
    Plastics Recycling EU
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Flecainide

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Phase III

    Sponsor : PhysIQ

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    physIQ Announces Collaboration with InCarda Therapeutics and Syneos Health to Accelerate Innovative Phase III ...

    Details : Partnering with physIQ and Syneos Health has allowed to develop and execute a patient-centric strategy to support the Phase 3 program of orally inhaled flecainide (Inrhythm) for acute cardioversion of recent-onset AF.

    Product Name : InRhythm

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    August 24, 2022

    Lead Product(s) : Flecainide

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase III

    Sponsor : PhysIQ

    Deal Size : Undisclosed

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    InCarda Therapeutics

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    InCarda Therapeutics

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Flecainide

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm Program

    Details : Based on these positive Phase 2 study results, along with recent interactions with the U.S. Food and Drug Administration (FDA), InCarda plans to conduct a single pivotal Phase 3 trial of InRhythm in patients with recent-onset PAF.

    Product Name : InRhythm

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    September 06, 2021

    Lead Product(s) : Flecainide

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    InCarda Therapeutics

    U.S.A arrow
    Plastics Recycling EU
    Not Confirmed

    InCarda Therapeutics

    U.S.A arrow
    Plastics Recycling EU
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Flecainide

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Phase II

    Sponsor : Deerfield Management

    Deal Size : $30.0 million

    Deal Type : Series C Financing

    DEALS_DEV arrow-down

    InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing

    Details : Proceeds from the financing will be used primarily to fund the ongoing clinical development of InRhythm™ (flecainide for inhalation), the company’s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation (PAF).

    Product Name : InRhythm

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    October 21, 2020

    Lead Product(s) : Flecainide

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase II

    Sponsor : Deerfield Management

    Deal Size : $30.0 million

    Deal Type : Series C Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    InCarda Therapeutics

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    InCarda Therapeutics

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Flecainide

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Phase II

    Sponsor : Innoviva

    Deal Size : Undisclosed

    Deal Type : Series C Financing

    DEALS_DEV arrow-down

    InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing

    Details : The European Commission said on Wednesday it had signed a contract on behalf of EU states with U.S. drugmaker Johnson & Johnson for the supply of 400 million doses of its COVID-19 vaccine candidate.

    Product Name : InRhythm

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    October 21, 2020

    Lead Product(s) : Flecainide

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase II

    Sponsor : Innoviva

    Deal Size : Undisclosed

    Deal Type : Series C Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Beximco Pharmaceuticals

    Bangladesh arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Beximco Pharmaceuticals

    Bangladesh arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Flecainide

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Beximco Pharma Receives US FDA Approval for Antiarryhtmic Drug Flecainide

    Details :

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    September 21, 2020

    Lead Product(s) : Flecainide

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth